Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial
2025; Elsevier BV; Volume: 54; Linguagem: Inglês
10.1016/j.vaccine.2025.127045
ISSN1873-2518
AutoresGonzalo Pérez Marc, Lorena M. Coria, Ana Ceballos, Juan M. Corchado, Mónica Lombardo, Laura Bruno, Federico Páez Córdoba, Clara G. Fascetto Cassero, Melina Salvatori, Mayra Rios Medrano, Fabiana Fulgenzi, María Fernanda Alzogaray, Analía Mykietiuk, Ignacio Leandro Uriarte, Nicolás Itcovici, Tomás Smith Casabella, Gonzalo Corral, Miriam Bruno, Oscar Roldán, Sebastián A Núñez, Florencia Cahn, G. Yerino, Alejandra Bianchi, Virginia Braem, Analía Christmann, Santiago Corradetti, Martín Claudio Darraidou, Lucila Di Nunzio, Tatiana Estrada, Rocío López Castelo, Carla Graciela Marchionatti, Lucila Pitocco, Virgina Macarena Trias Uriarte, Cristian Wood, Romina Zadoff, Florencia Bues, Rosa M. Urbanos-Garrido, Emanuele Montomoli, Alessandro Manenti, Agostina Demaría, Lineia Prado, Celeste Pueblas Castro, Lucas Saposnik, Jorge Geffner, Federico Montes de, Julio C. Vega, Juan Fló, Pablo Bonvehí, Jorge Cassará, Karina A. Pasquevich, Juliana Cassataro,
Tópico(s)Heparin-Induced Thrombocytopenia and Thrombosis
Referência(s)